Hypertension

On September 7, 2023, Alnylam Pharmaceuticals announced positive topline data from the phase 2 KARDIA-1 trial of zilbesiran in the treatment of hypertension.

The FDA Circulatory System Devices Panel has voted in favor of the benefit-risk profile of Recor Medical's RDN system in a 10-2 vote but declined to endorse Medtronic's system in a 6-7 vote.

Hypertension prevalence was significantly higher among adults with obesity and severe NAFLD, providing important information related to the association between hypertension and NAFLD severity.

An analysis of data from a NYC-based health system indicate more than 1 in 5 people hospitalized for COVID-19 and 1 in 10 nonhospitalized COVID-19 patients went on to develop persistent hypertension 6 months later.

The July 2023 cardiology month in review features a Class I recall from the FDA, the latest recommendation statement from the USPSTF, and an update on 3 agents in the pipeline.

An analysis of 7 international, longitudinal studies with nearly 20,000 patients details apparent increases in risk associated with daily alcohol consumption among healthy adults.

A multipart, phase 1 trial provides evidence demonstrating the safety of zilebesiran, an RNA interference agent, which appeared to have a favorable safety profile among adult patients with hypertension.

A new analysis presented at ADA 2023 recommended effective diabetic retinopathy screening for patients with T2D and hypertension.

However, results from the Vet-COACH trial reported a significant improvement in mental health–related quality of life in the intervention group compared with the control group.

Data from the SPRINT MIND trial suggests intensive blood pressuring-lowering was associated with slower increases in white matter lesions and improved cerebral blood flow.

A cross-sectional analysis of data is offering a snapshot of trends in the treatment of 7 common chronic health conditions among incarcerated populations in the US relative to the general population.

A double-blind, repeated crossover trial suggests personalized treatment for blood pressure could yield an additional 4.4 mmHg reduction in systolic blood pressure.

The latest scientific statement from the American Heart Association takes aim at offering clinicians with a summary of contemporary evidence related to the prevalence and increase in long-term risk associated with hypertension in children and adolescents.

A remote hypertension management program at Mass General Brigham was associated with significant improvements in blood pressure control despite systemic disruptions in care due to the COVID‐19 pandemic.

Children living in areas with greater neighborhood deprivation in the US have a higher likelihood of being diagnosed with primary hypertension, according to an analysis of more than 65,000 children.

An analysis of data from a 50-year prospective study provides insight into the effects of different pregnancy complications on all-cause mortality later in life.

An analysis of more than 800,000 children with more than 3.5 million person-years of follow-up indicate those in the upper range of average BMI had a 26% greater risk of developing hypertension, with each per unit increase in BMI associated with a 4% increase in risk of hypertension.

At ACC 2023, Hoeper provides insight into the key efficacy findings of STELLAR and delves into the safety concerns and generalizability of sotatercept for PAH.

Hear from Deepak Bhatt, MD, MPH, as he discusses how he interprets the results of the HALO trial and offers perspective on the forthcoming research related to baxdrostat.

Results from the phase 3 A DUE study suggest a combination of macitentan and tadalafil nearly doubled reductions in pulmonary vascular resistance in patients with PAH.

Data from the phase 3 STELLAR trial indicate adding sotatercept to background therapy in PAH was associated with statistically significant improvements in 6-minute walk distance and 8 of the trial's 9 secondary endpoints, including time to death or clinical worsening.

At ACC 2023, HCPLive editorial team sat down with Clyde Yancy, MD, to learn more about his perspective on recent and upcoming advances in cardiovascular care. In this interview, Yancy discusses his perspective on the clinical trial data surrounding renal denervation as a treatment for hypertension.

A genome-wide genetic association study using mendelian randomization provides insight into the causal relationships between HDPs and coronary artery disease and ischemic stroke later in life.

A study presented at the International Stroke Conference 2023 suggests the plasma metabolite gluconic acid could serve as a race-specific biomarker for identifying increased risk of hypertension and stroke in Black adults.

The SPRINT MIND trial is providing new evidence related to the effects of intensive blood pressure lowering on cognitive impairment and risk of dementia according to baseline diastolic blood pressure